Prenatal Aspirin Not Linked to Adverse Infant Outcomes
Drug not significantly associated with mortality, cerebral lesions or palsy, or cognitive impairment
MONDAY, Dec. 21 (HealthDay News) -- Among infants born preterm, low-dose aspirin (LDA) during pregnancy is not associated with fetal or infant deaths, infant cerebral damage, or brain development disorders, according to research published online Dec. 21 in Pediatrics.
Stéphane Marret, M.D., of the Rouen University Hospital in France, and colleagues analyzed data from 656 children born to 584 women with issues including history of preeclampsia, fetal growth restriction, chronic hypertension or renal disease. Of these women, 125 received LDA during pregnancy. The children were given a neuropsychological examination at 5 years of age.
The researchers found that aspirin was not significantly associated with any neonatal outcomes. At 5 years of age, aspirin was not associated with cerebral palsy rate, nor was it associated with low mental processing composite scores on the Kaufman Assessment Battery for Children. However, aspirin was linked to a reduction of borderline statistical significance in total behavioral difficulties and hyperactivity.
"To our knowledge, this is the first study to examine the effects of LDA in such a homogenous population of very preterm newborns. We found that antenatal LDA was not associated with adverse neonatal or long-term outcomes. Moreover, the results of our study suggest that LDA may be associated with a reduction in neurobehavioral difficulties. However, these results should be interpreted with caution and need to be confirmed," the authors conclude.